This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Sophie Ochonisky, MD; Josette Verroust, MD; Sylvie Bastuji-Garin, MD; Romain Gherardi, MD; Jean Revuz, MD

Arch Dermatol. 1994;130(1):66-69.

Abstract
Background and Design
Thalidomide therapy was shown to be effective in numerous dermatologic diseases. As reliable methods of contraception are now available, neurotoxicity has become the most important side effect limiting the use of thalidomide. The incidence of this neuropathy and its relationship to thalidomide doses are still matters of debate. In a retrospective study, we reviewed the files of 42 patients who had received thalidomide between 1987 and 1992 for various dermatologic diseases. The incidence and the conditions of occurrence of the neuropathy were analyzed.

Results
Evidence of a thalidomide-induced neuropathy was present in nine patients (21%), who had both clinical and electrophysiologic typical abnormalities. Twelve other patients (28%), however, presented with isolated clinical or electrophysiologic signs. Thus, the diagnosis of thalidomide neuropathy could not be affirmed. The occurrence of the neuropathy did not appear to be related to the daily dose nor to the duration of treatment. The highest risk of developing a thalidomide neuropathy was found in female and elderly patients. Two monozygotic twin sisters, who received thalidomide for Behçet's disease, both developed a neuropathy.

Conclusions
These data suggest that the incidence of thalidomide neuropathy may be between 21% and 50%. Individual susceptibilities with possible genetic predisposition seem to be more important than daily dose and duration of thalidomide therapy.

(Arch Dermatol. 1994;130:66-69)

Author Affiliations
From the Departments of Dermatology (Drs Ochonisky, Bastuji-Garin, and Revuz), Neurophysiology (Dr Verroust), and Pathology (Dr Gherardi), Hôpital Henri Mondor, Créteil, France.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi et al.
JCO 2009;27:4563-4569.
ABSTRACT | FULL TEXT  

Thalidomide and sensory neurotoxicity: a neurophysiological study
Zara et al.
J. Neurol. Neurosurg. Psychiatry 2008;79:1258-1261.
ABSTRACT | FULL TEXT  

Development of Neuropathy in Patients With Myeloma Treated With Thalidomide: Patterns of Occurrence and the Role of Electrophysiologic Monitoring
Mileshkin et al.
JCO 2006;24:4507-4514.
ABSTRACT | FULL TEXT  

Treatment of Behcet's syndrome
Barnes
Rheumatology (Oxford) 2006;45:245-247.
FULL TEXT  

Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus: a 65 series of Brazilian patients
Coelho et al.
Lupus 2005;14:434-439.
ABSTRACT  

Effects of Thalidomide on Developmental, Peri- and Postnatal Function in Female New Zealand White Rabbits and Offspring
Teo et al.
Toxicol Sci 2004;81:379-389.
ABSTRACT | FULL TEXT  

Thalidomide Treatment for Prurigo Nodularis in Human Immunodeficiency Virus-Infected Subjects: Efficacy and Risk of Neuropathy
Maurer et al.
Arch Dermatol 2004;140:845-849.
ABSTRACT | FULL TEXT  

Thalidomide neuropathy: Too much or too long?
Apfel and Zochodne
Neurology 2004;62:2158-2159.
FULL TEXT  

Thalidomide sensory neurotoxicity: A clinical and neurophysiologic study
Cavaletti et al.
Neurology 2004;62:2291-2293.
ABSTRACT | FULL TEXT  

The Schizophrenic Career of a "Monster Drug"
Crawford
Pediatrics 2003;111:712-712.
FULL TEXT  

Thalidomide and its derivatives: emerging from the wilderness
Gordon and Goggin
Postgrad. Med. J. 2003;79:127-132.
ABSTRACT | FULL TEXT  

Low-Dose Thalidomide Therapy for Refractory Cutaneous Lesions of Lupus Erythematosus
Housman et al.
Arch Dermatol 2003;139:50-54.
ABSTRACT | FULL TEXT  

Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit
Wozniacka et al.
Lupus 2002;11:71-81.
ABSTRACT  

Update on therapy -- thalidomide in the treatment of lupus
Karim et al.
Lupus 2001;10:188-192.
ABSTRACT  

Safety Profile of Thalidomide after 53 Weeks of Oral Administration in Beagle Dogs
Teo et al.
Toxicol Sci 2001;59:160-168.
ABSTRACT | FULL TEXT  

Lack of peripheral neuropathy in Beagle dogs after 53 weeks oral administration of thalidomide capsules
Teo et al.
Hum Exp Toxicol 2000;19:615-622.
ABSTRACT  

New therapies for heart failure: is thalidomide the answer?
Davey and Ashrafian
QJM 2000;93:305-311.
ABSTRACT | FULL TEXT  

American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus
Duong et al.
Arch Dermatol 1999;135:1079-1087.
ABSTRACT | FULL TEXT  

Peripheral Neuropathy in HIV Disease
AIDS Clin Care 1998;1998:1-1.
FULL TEXT  

The place of thalidomide in the treatment of inflammatory disease
Stevens
Lupus 1996;5:257-258.
 

Crossover Study of Thalidomide vs Placebo in Jessner's Lymphocytic Infiltration of the Skin
Guillaume et al.
Arch Dermatol 1995;131:1032-1035.
ABSTRACT  

Safety of thalidomide
Crawford
BMJ 1994;308:1437-38.
FULL TEXT